Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01680653 · ClinicalTrials.gov registry record · NA
Testing State of the Art Remote Glucose Monitoring at Diabetes Camp
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT01680653: Completed NA study, sponsored by Stanford University.
NCT01680653 is a NA study that has completed, run by Stanford University. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01680653, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
The incidence of low blood sugar and hypoglycemic seizures at diabetes camp has been reduced thanks to overnight blood glucose level testing. The timing of the overnight blood test is often arbitrary and it is unclear when the highest frequency of nocturnal hypoglycemic events at camp are occurring. It is also unclear what the most appropriate treatment for nocturnal hypoglycemia is: simple carbohydrates, or mini-glucagon. In this study, we will use Continuous Glucose Monitors (CGMs) that will send subject data securely to a remote computer located in the medical cottage at camp throughout the night. Study staff will monitor the computer and will intervene on low blood sugar as it occurs in real time. On half of the nights, campers will receive mini-glucagon for low blood sugar, and on the rest, they will receive standard carbohydrate treatment.
Primary Outcome
Number of minutes with glucose reading \< 50 mg/dL. Each camper had Remote Monitoring nights and Control nights.
Interventions
- DRUG Mini-glucagon
- DEVICE Remote monitoring
- DIETARY_SUPPLEMENT Carbohydrates
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-09 |
| Phase | NA |
What the finished NCT01680653 record still lists
NCT01680653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Mini-glucagon is the first listed.
NCT01680653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01680653 about?
NCT01680653 is a clinical study titled "Testing State of the Art Remote Glucose Monitoring at Diabetes Camp". The incidence of low blood sugar and hypoglycemic seizures at diabetes camp has been reduced thanks to overnight blood glucose level testing. The timing of the overnight blood test is often arbitrary and it is unclear when the highest frequency of nocturnal hypoglycemic events at camp are occurring....
What is the current status of trial NCT01680653?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2012-05. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01680653?
The interventions under investigation include: Mini-glucagon (DRUG), Remote monitoring (DEVICE), Carbohydrates (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01680653?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01680653's enrollment target sits among peer trials
57 1261st of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia